New therapies, revised regimens, trends, and of course COVID-19 are all on the list.

Uno studio di fase III ha valutato gli effetti dell’antagonista del recettore dei mineralcorticoidi sugli outcome renali e cardiovascolari.

Synopsis covers care needs, glycemic monitoring, lifestyle, glucose-lowering, care approaches.

Investigational mineralocorticoid receptor antagonist reduced CKD progression and CV events.

AKI is both precursor and consequence of CKD.

The European Medicines Agency has approved a new indication for sucroferric oxyhydroxide.

Risultati della sperimentazione DAPA-CKD.

Study suggests a potential treatment option for patients with psoriasis and hyperlipidemia.

Proportion with eGFR <30 mL/minute/1.73 m2 has doubled within 3 years.

Real-world data suggest a class effect.

Evidence-based recommendations incorporate new therapies.

Authors lay blame on systemic illness following on severe infection.

Lo studio clinico CKD-FIX ha testato l’ipotesi che i livelli di acido urico circolante abbiano un ruolo causale nella progressione della malattia.

Cystatin C closely aligns with kidney function.